Ambu AMBU-B.CO
DenmarkHealthcare · Medical DevicesNasdaq Copenhague · DKK
81.77 DKK (+16.6%)
7 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Ambu A/S is a Danish manufacturer of single-use medical devices, specializing in visualization (disposable endoscopy), anesthesia, and patient care, selling to hospitals and healthcare systems globally.
Listed on Nasdaq Copenhague · Symbol AMBU-B.CO · CPH: AMBU-B · Currency DKK
Key points
from its scores- ✓Very solid balance sheet7.7
- ✓Strong growth7.4
- ✕Poor share-price trend1.0
- ✕Demanding valuation3.1
- ✕Little or no dividend4.3
AI analysis
bottom line, main risk, context and newsFundamentals are decent but valuation offers no margin of safety and negative momentum suggests waiting for a better entry point.
Ambu shows solid financial health (net cash, liquidity 2.77) and double-digit growth (revenue +8.8%, earnings +28.3%), but its valuation is demanding (P/E 36.51, EV/EBITDA 21.18) and momentum is very negative (-36.3% over 12 months), reflecting market doubts about its execution and competition.
The sharp 36% decline over the past year and low momentum (score 1.02) indicate competitive pressure and potential erosion of market confidence in Ambu's execution, despite its solid fundamentals.
Context and risks
Ambu has no material exposure to current macro factors: its single-use medical device business does not depend significantly on commodities, shipping routes, or interest rates, and its balance sheet shows net cash. The main risk is company-specific: the sharp 36% decline over the past year reflects competitive and execution pressures, not a macro factor.
Is Ambu stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 41% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 36.5 | 26.7 | +37% |
| EV / EBITDA | 21.2 | 14.5 | +46% |
| Price / book | 3.0 | 4.1 | −27% |
| Price / sales | 2.9 | 3.4 | −14% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 81.77 DKK, +16.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 5.5 (sector 5.5), Growth 7.4 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 36.5
- Forward P/E
- 23.1
- EV / EBITDA
- 21.2
- Price / book
- 3.0
- Price / sales
- 2.9
- PEG
- 2.85
- Market cap
- 18.3B DKK
- Enterprise value
- 18.4B DKK
Profitability
- ROE
- 8.4%
- ROA
- 5.8%
- ROIC (approx.)
- 12.6%
- Gross margin
- 60.1%
- Operating margin
- 13.5%
- Net margin
- 8.2%
- Free cash flow
- 206.5M DKK
- FCF yield
- 1.1%
- Cash conversion
- 24%
Solvency
- Total debt
- 579.0M DKK
- Net debt
- −126.0M DKK
- Cash
- 705.0M DKK
- EBITDA
- 869.0M DKK
- Net debt / EBITDA
- −0.14
- Debt / equity
- 9.39
- Current ratio
- 2.77
- Quick ratio
- 1.58
Growth
- Revenue growth
- +8.8%
- Earnings growth
- +28.3%
- EPS (TTM)
- 1.92 DKK
- EPS (forward)
- 3.04 DKK
Dividend
- Dividend yield
- 0.6%
- Payout
- 21.4%
Risk and market
- Beta
- 1.38
- Analyst consensus
- Hold (7)
- Target price
- 81.77 DKK
- 52-week range
- 56.25 – 109.00
Recent news
All AMBU-B.CO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Ambu
Is Ambu stock cheap or expensive?
On P/E and EV / EBITDA, it trades 41% above the Healthcare median on average. Valuation score: 3.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 81.77 DKK, +16.6% versus the price. This is not investment advice.
What score does Ambu get on MeridIAn Screener?
It scores 5.0 out of 10, rank 1,686 of 2,130 (better than 19% of the companies analysed). Its strongest category is Financial health (7.7) and its weakest, Momentum (1.0). Analysis of 08/10/2026.
What is Ambu's P/E ratio?
Its P/E is 36.5: the share price equals 36.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 23.1.
How much is Ambu worth on the stock market?
Its market capitalisation is 18.3B DKK and its enterprise value, debt included, is 18.4B DKK.
How much debt does Ambu have?
It has more cash than debt: net cash of 126.0M DKK.
Does Ambu pay a dividend?
Yes: its dividend yield is 0.58% and it pays out 21% of its earnings.
How has Ambu stock performed over the last year?
It has fallen 31.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 56.25 and 109.00 DKK. Past performance does not guarantee future results.
What do analysts think of Ambu?
7 analysts cover it; their average recommendation is “Hold” and their average target is 81.77 DKK (+16.6% versus the price). It is an estimate, not market data.